|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Clinical Research Evaluating the Safety and Efficacy of CD70-targeted CAR-NKT Cells (CGC738) Therapy in Subjects with Advanced Malignant Solid Tumors
This is a phase I, open-label, single-arm study conducted to evaluate the efficacy, safety and PK of CGC738 in the treatment of advanced malignant solid tumors.
Condition or disease:advanced malignant solid tumors Intervention/treatment:Biological: CD70 CAR-NKT cells Phase:Phase 1
100 Clinical Results associated with Suzhou Cure Genetics Co., Ltd.
0 Patents (Medical) associated with Suzhou Cure Genetics Co., Ltd.
100 Deals associated with Suzhou Cure Genetics Co., Ltd.
100 Translational Medicine associated with Suzhou Cure Genetics Co., Ltd.